CO7131358A2 - Compuestos de n-alquiltriazol como antagonistas de lpar - Google Patents
Compuestos de n-alquiltriazol como antagonistas de lparInfo
- Publication number
- CO7131358A2 CO7131358A2 CO14256136A CO14256136A CO7131358A2 CO 7131358 A2 CO7131358 A2 CO 7131358A2 CO 14256136 A CO14256136 A CO 14256136A CO 14256136 A CO14256136 A CO 14256136A CO 7131358 A2 CO7131358 A2 CO 7131358A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- alkyltriazole
- lpar antagonists
- lpar
- antagonists
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661961P | 2012-06-20 | 2012-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7131358A2 true CO7131358A2 (es) | 2014-12-01 |
Family
ID=48628667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14256136A CO7131358A2 (es) | 2012-06-20 | 2014-11-21 | Compuestos de n-alquiltriazol como antagonistas de lpar |
Country Status (22)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014003499A2 (pt) | 2011-08-15 | 2017-06-13 | Intermune Inc | compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula |
| KR20150011389A (ko) * | 2012-06-20 | 2015-01-30 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서 n-아릴트라이아졸 화합물 |
| CN105142635B (zh) | 2013-03-15 | 2021-07-27 | 艾匹根生物技术有限公司 | 有用于治疗疾病的杂环化合物 |
| AU2015281021B9 (en) | 2014-06-27 | 2019-03-28 | Ube Corporation | Salt of halogen-substituted heterocyclic compound |
| AR108838A1 (es) * | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| ES2925626T3 (es) | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
| WO2019126093A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
| ES2943661T3 (es) | 2017-12-19 | 2023-06-15 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos pirazol-O-ligados como antagonistas de LPA |
| KR102698386B1 (ko) | 2017-12-19 | 2024-08-22 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산 |
| JP7256807B2 (ja) * | 2017-12-19 | 2023-04-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール |
| AR113965A1 (es) * | 2017-12-19 | 2020-07-01 | Bristol Myers Squibb Co | Triazol azoles ciclohexil ácidos como antagonistas de lpa |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| CN112041029B (zh) | 2017-12-19 | 2025-01-24 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸吡唑唑类 |
| KR102828422B1 (ko) | 2017-12-19 | 2025-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 이속사졸 아진 |
| HUE057366T2 (hu) * | 2017-12-19 | 2022-05-28 | Bristol Myers Squibb Co | Tirazol-N-összekapcsolt karbamoil ciklohexil savak mint LPA antagonisták |
| IL297802A (en) * | 2017-12-29 | 2022-12-01 | Biomarin Pharm Inc | Glycolate oxidase inhibitors to treat the disease |
| US20210317131A1 (en) * | 2018-09-18 | 2021-10-14 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| US12209072B2 (en) | 2018-09-18 | 2025-01-28 | Bristol-Myers Squibb Company | Cyclopentyl acids as LPA antagonists |
| US20220041572A1 (en) * | 2018-09-18 | 2022-02-10 | Bristol-Myers Squibb Company | Cycloheptyl acids as lpa antagonists |
| KR102775995B1 (ko) * | 2019-11-15 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| AU2021282986B2 (en) | 2020-06-03 | 2024-03-07 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4337641A1 (en) | 2021-05-11 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) * | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159550A2 (en) | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| KR20130126659A (ko) * | 2010-12-07 | 2013-11-20 | 아미라 파마슈티칼스 인코포레이티드 | 리소포스파티드산 수용체 길항제 및 섬유증 치료에서의 그의 용도 |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| BR112014003499A2 (pt) | 2011-08-15 | 2017-06-13 | Intermune Inc | compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula |
-
2013
- 2013-06-17 US US14/401,009 patent/US9321738B2/en not_active Expired - Fee Related
- 2013-06-17 IN IN9348DEN2014 patent/IN2014DN09348A/en unknown
- 2013-06-17 PE PE2014002232A patent/PE20142448A1/es not_active Application Discontinuation
- 2013-06-17 CN CN201380032285.0A patent/CN104411692A/zh active Pending
- 2013-06-17 KR KR1020147035768A patent/KR20150021057A/ko not_active Ceased
- 2013-06-17 AU AU2013279512A patent/AU2013279512A1/en not_active Abandoned
- 2013-06-17 CA CA2869541A patent/CA2869541A1/en not_active Abandoned
- 2013-06-17 EA EA201492285A patent/EA201492285A1/ru unknown
- 2013-06-17 SG SG11201407220YA patent/SG11201407220YA/en unknown
- 2013-06-17 MA MA37764A patent/MA37764A1/fr unknown
- 2013-06-17 EP EP13729330.4A patent/EP2864300A1/en not_active Withdrawn
- 2013-06-17 MX MX2014014710A patent/MX2014014710A/es unknown
- 2013-06-17 JP JP2015517704A patent/JP2015520202A/ja not_active Ceased
- 2013-06-17 HK HK15106927.8A patent/HK1206342A1/xx unknown
- 2013-06-17 WO PCT/EP2013/062461 patent/WO2013189864A1/en active Application Filing
- 2013-06-17 BR BR112014030685A patent/BR112014030685A2/pt not_active Application Discontinuation
- 2013-06-17 UA UAA201500428A patent/UA109868C2/ru unknown
-
2014
- 2014-11-17 CR CR20140525A patent/CR20140525A/es unknown
- 2014-11-21 CO CO14256136A patent/CO7131358A2/es unknown
- 2014-11-28 CL CL2014003243A patent/CL2014003243A1/es unknown
- 2014-12-04 IL IL236088A patent/IL236088A0/en unknown
- 2014-12-15 PH PH12014502789A patent/PH12014502789A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150021057A (ko) | 2015-02-27 |
| SG11201407220YA (en) | 2014-12-30 |
| PE20142448A1 (es) | 2015-01-28 |
| CL2014003243A1 (es) | 2015-03-20 |
| WO2013189864A1 (en) | 2013-12-27 |
| EP2864300A1 (en) | 2015-04-29 |
| PH12014502789A1 (en) | 2015-02-09 |
| MA37764A1 (fr) | 2016-01-29 |
| CR20140525A (es) | 2015-01-12 |
| UA109868C2 (ru) | 2015-10-12 |
| EA201492285A1 (ru) | 2015-04-30 |
| US20150133511A1 (en) | 2015-05-14 |
| MX2014014710A (es) | 2015-03-04 |
| US9321738B2 (en) | 2016-04-26 |
| IN2014DN09348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-17 |
| CN104411692A (zh) | 2015-03-11 |
| BR112014030685A2 (pt) | 2017-06-27 |
| AU2013279512A1 (en) | 2014-10-16 |
| IL236088A0 (en) | 2015-02-01 |
| HK1206342A1 (en) | 2016-01-08 |
| JP2015520202A (ja) | 2015-07-16 |
| CA2869541A1 (en) | 2013-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CU20160167A7 (es) | Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| PE20180318A1 (es) | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| CL2014001174A1 (es) | Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades. | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| DOP2014000152A (es) | Inhibidores de bromodominios | |
| UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
| UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
| CU20150021A7 (es) | Piridinonas bicíclicas novedosas | |
| ECSP14013215A (es) | Compuestos novedosos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| CR20130318A (es) | Nuevos compuestos de benzodioxol-piperazina | |
| ECSP10010597A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| CU20100210A7 (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas |